Angiosarcoma Clinical Trials

12 recruiting

Angiosarcoma Trials at a Glance

14 actively recruiting trials for angiosarcoma are listed on ClinicalTrialsFinder across 6 cities in 11 countries. The largest study group is Phase 2 with 8 trials, with the heaviest enrollment activity in Lille, Marseille, and Besançon. Lead sponsors running angiosarcoma studies include Federation Francophone de Cancerologie Digestive, Fudan University, and Centre Leon Berard.

Browse angiosarcoma trials by phase

Treatments under study

About Angiosarcoma Clinical Trials

Looking for clinical trials for Angiosarcoma? There are currently 12 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Angiosarcoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Angiosarcoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 114 of 14 trials

Recruiting
Phase 1Phase 2

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

AngiosarcomaLiposarcomaAdipocytic Neoplasm+6 more
St. Jude Children's Research Hospital139 enrolled6 locationsNCT06239272
Recruiting
Phase 2

Agnostic Therapy in Rare Solid Tumors

Cancer of Unknown PrimarySoft Tissue SarcomaCholangiocarcinoma+38 more
Instituto do Cancer do Estado de São Paulo28 enrolled8 locationsNCT06638931
Recruiting
Phase 2

Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma

AngiosarcomaAngiosarcoma, Adult
Varun Monga, MBBS18 enrolled1 locationNCT06898970
Recruiting
Phase 2

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Breast CancerBreast NeoplasmsHER2-negative Breast Cancer+6 more
QuantumLeap Healthcare Collaborative5,000 enrolled42 locationsNCT01042379
Recruiting

Precision Medicine Approaches for Neoadjuvant Therapy in High-risk Sarcoma Patients

SarcomaAngiosarcomaSoft Tissue Sarcoma (STS)+9 more
Royal Marsden NHS Foundation Trust800 enrolled1 locationNCT07432932
Recruiting

Cardiac Angiosarcoma International Registry

Cardiac Angiosarcoma
Immune Oncology Research Institute500 enrolled1 locationNCT06715579
Recruiting
Not Applicable

Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas

AngiosarcomaOsteosarcomaEwing Sarcoma+4 more
Centre Leon Berard168 enrolled16 locationsNCT04055220
Recruiting
Phase 2

IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)

AngiosarcomaLeiomyosarcomaDesmoplastic Small Round Cell Tumor+4 more
Fudan University45 enrolled1 locationNCT06849986
Recruiting
Phase 1

A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer

MelanomaHead and Neck Squamous Cell CarcinomaMetastatic Cancer+16 more
Memorial Sloan Kettering Cancer Center56 enrolled7 locationsNCT05859074
Recruiting

Prospective Observational Study of Localized Angiosarcoma of Any Site: ProStars

Angiosarcoma
Italian Sarcoma Group250 enrolled19 locationsNCT06375941
Recruiting
Phase 2

Pembrolizumab Plus Lenvatinib in Unresectable Cutaneous Angiosarcoma Patients

Angiosarcoma of SkinAngiosarcoma Metastatic
National Cancer Center, Japan38 enrolled5 locationsNCT06673628
Recruiting

A French Multicenter Observational Retrospective Study of Rare Primary Liver Cancers

CholangiocarcinomaHepatoblastomaFibrolamellar Carcinoma+7 more
Federation Francophone de Cancerologie Digestive150 enrolled40 locationsNCT06541652
Recruiting
Phase 2

MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma

AngiosarcomaLeiomyosarcomaSynovial Sarcoma+8 more
HRYZ Biotech Co.148 enrolled1 locationNCT06277154
Recruiting
Phase 2

Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients

AngiosarcomaSoft Tissue Sarcoma AdultUndifferentiated Pleomorphic Sarcoma
Niels Junker80 enrolled4 locationsNCT05961761